163 related articles for article (PubMed ID: 25275915)
1. Noninvasive ocular drug delivery: potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma.
Foldvari M
J Glaucoma; 2014; 23(8 Suppl 1):S80-2. PubMed ID: 25275915
[TBL] [Abstract][Full Text] [Related]
2. Corneal thickness and glaucoma medications.
Mehdizadeh M; Jamshidian-Tehrani M; Nowroozzadeh MH
Ophthalmology; 2009 Jul; 116(7):1416-7; author reply 1417, 1417.e1. PubMed ID: 19576505
[No Abstract] [Full Text] [Related]
3. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
4. Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.
Katsanos A; Dastiridou AI; Fanariotis M; Kotoula M; Tsironi EE
J Ocul Pharmacol Ther; 2011 Feb; 27(1):67-71. PubMed ID: 21214361
[TBL] [Abstract][Full Text] [Related]
5. Relative efficacy of prostaglandins.
Laxmana Rao HB; Sekhar GC
Ophthalmology; 2009 Jul; 116(7):1418; author reply 1418-9. PubMed ID: 19576507
[No Abstract] [Full Text] [Related]
6. Current and new pharmacotherapeutic approaches for glaucoma.
Shalaby WS; Shankar V; Razeghinejad R; Katz LJ
Expert Opin Pharmacother; 2020 Nov; 21(16):2027-2040. PubMed ID: 32717157
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
8. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
9. [Topical prostaglandins influence over cornea--preliminary report].
Wierzbowska J; Stankiewicz A
Klin Oczna; 2006; 108(10-12):479-81. PubMed ID: 17455732
[TBL] [Abstract][Full Text] [Related]
10. Potential drug delivery approaches for XFS-associated and XFS-associated glaucoma.
Kulkarni SS; Kompella UB
J Glaucoma; 2014; 23(8 Suppl 1):S77-9. PubMed ID: 25275914
[TBL] [Abstract][Full Text] [Related]
11. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
[TBL] [Abstract][Full Text] [Related]
12. The medical management of primary open-angle glaucoma in the elderly patient.
Schoevaerdts D; Levecq L; Vanpee D; Swine C
Z Gerontol Geriatr; 2003 Apr; 36(2):121-3. PubMed ID: 12720024
[TBL] [Abstract][Full Text] [Related]
13. Barriers to glaucoma drug delivery.
Ghate D; Edelhauser HF
J Glaucoma; 2008 Mar; 17(2):147-56. PubMed ID: 18344762
[TBL] [Abstract][Full Text] [Related]
14. Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy.
Monaco G; Cacioppo V; Consonni D; Troiano P
Eur J Ophthalmol; 2011; 21(3):243-50. PubMed ID: 20872359
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Eye Drop Instillation Before and After Use of Drop Application Strips in Glaucoma Patients on Chronic Topical Therapy.
Sharma R; Singhal D; Shashni A; Agarwal E; Wadhwani M; Dada T
J Glaucoma; 2016 Apr; 25(4):e438-40. PubMed ID: 26550965
[TBL] [Abstract][Full Text] [Related]
16. Liposomes in topical ophthalmic drug delivery: an update.
Agarwal R; Iezhitsa I; Agarwal P; Abdul Nasir NA; Razali N; Alyautdin R; Ismail NM
Drug Deliv; 2016 May; 23(4):1075-91. PubMed ID: 25116511
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
[TBL] [Abstract][Full Text] [Related]
18. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
[TBL] [Abstract][Full Text] [Related]
19. Ocular Redness Measured with the Keratograph 5M in Patients Using Anti-Glaucoma Eye Drops.
Pérez Bartolomé F; Martínez de la Casa JM; Arriola Villalobos P; Fernández Pérez C; Polo V; Sánchez Jean R; García Feijoó J
Semin Ophthalmol; 2018; 33(5):643-650. PubMed ID: 29144869
[TBL] [Abstract][Full Text] [Related]
20. Effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% administered in the evening in glaucoma.
Polo V; Larrosa JM; Ferreras A; Borque E; Pablo LE; Honrubia FM
Ann Ophthalmol (Skokie); 2008; 40(3-4):157-62. PubMed ID: 19230353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
